Evolent Health Q3 2022 revenue up 58.5% to $352.6M; net income $2.1M

Evolent Health, Inc.

2022-Q3 EPS reported -$0.09 revenue$352,585,000

Revenue of $352.6M, +58.5% YoY; net income $2.1M (0.6% margin).
Adjusted EBITDA of $28.1M (8.0% margin), vs prior-year loss.
Total lives on platform 19.5M; EHS 2.1M, Clinical Solutions 17.4M.
Signed 3 new operating partnerships, including Molina Healthcare expansion and WA ACO for 2023 MSSP.
Dan McCarthy promoted to President; Kali Beyah appointed Chief People and Brand Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. reported the quarter ended September 30, 2022 results: revenue $352.6 million, net income $2.1 million.

Period: the quarter ended September 30, 2022
Revenue: $352.6 million
Net income: $2.1 million
Result: reported results

Exact text from the filing

Quarter ended September 30, 2022: • Revenue of $352.6 million, an increase of $130.1 million, or 58.5%, from the three months ended September 30, 2021. • Net income attributable to common shareholders of Evolent Health, Inc. of $2.1 million resulting in a net income margin of 0.6%.

View on SEC.gov

Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-22-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.